anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1381019 Separator containers for centrifuges BECTON DICKINSON & CO 28 Dec 1972 [25 April 1972] 598-17/72 Heading B2P [Also in Division B8] An apparatus for separating blood into a light phase, i.e. the serum or plasma, and a heavy phase, i.e. the cells, when subjected to centrifugal force in a centrifuge comprises a container 12 for receiving the blood to be separated; a piston 50 slidably mounted in the container with its periphery making a fluidtight seal with the container; stop means 34 in the container for limiting movement of the piston so that it can slide from one end of the container to a position spaced from the opposite end of the container; and normally closed valve means 44 incorporated in the piston and arranged to open in response to a fluid pressure differential between the two sides of the piston whereby the light phase will during centrifugation pass from one side of the piston to the other side through the open valve means, as the piston slides in the container under the action of centrifugal force, and thereafter becomes separated from the heavy phase when the valve means close upon the pressure differential becoming nil as the piston comes to rest against the stop means 34. The container 12 may be madeof glass and is closed at its ends by closures 14, 16 made of a self-sealing elastomer, e.g. rubber. Blood is supplied to the interior of the container through a removable cannula or hollow needle 18. The stop means 34 consists of a constriction formed on the inner surface of the container by an annular groove 32. The piston 40 is formed of elastomeric material and is provided with an annular recess 54 in which a tubular metal, e.g. stainless steel, insert 52 is mounted with an interference fit. Formed integrally with the piston are axially spaced resilient sealing rings 50. The top wall portion of the piston which constitutes the valve means 44 is in the form of a diaphragm made of relatively thin, stretchable or resilient material provided with a plurality of normally closed apertures 42 in the form of self-sealing slits extending therethrough. A cylindrical axial recess 80 is provided in the piston for passage of the light phase towards the valve means 42. In a modification, Fig. 5 (not shown), a filter (60) is mounted in the recess 80 to prevent any fibrin from passing through the valve means 42. The filter may be of asbestos, glass wool, a plastic foam or paper.
According to certain embodiments, a method in a network node is disclosed. The method comprises selecting a subset from a predetermined set of P CSI-RS ports for receiving channel information. The network node comprises an antenna array with controllable polarization. Each CSI-RS port corresponds to a combination of a set of resource elements and an antenna port of said antenna array. The predetermined set comprises a first number P| of CSI-RS ports with a first polarization state and a second number P2 of CSI-RS ports with a second polarization state. The first and second polarization states are distinct. The method further comprises populating the subset with Q CSI-RS ports in such manner that the ratio of CSI-RS ports respectively having the first and second polarization states is equal to the ratio of the first and second numbers.
The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of zonisamide capsules to an equivalent dose of a reference formulation, Zonegran® (zonisamide) capsules, after a single oral dose administered under fasting conditions.

Thirty-four healthy, non-smoking, non-obese male and female volunteers at least 18 years of age will be randomly assigned in a crossover fashion to receive each of two zonisamide dosing regimens in sequence with a 28 day washout period between dosing periods. On the morning of Day 1, after an overnight fast, subjects will receive either a single oral dose of the test formulation, zonisamide (1 x 100 mg capsule) or a single oral dose of the reference formulation, Zonegran® (1 x 100 mg capsule). After a 28 day washout period, on the morning of Day 29 after an overnight fast, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 72 hours post dose at times sufficient to adequately define the pharmacokinetics of zonisamide. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drug and/or procedures. Blood pressure and heart rate will be obtained prior to dosing and as scheduled following dose administration. All adverse events whether elicited by query, spontaneously reported or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.
AIM: Hypoxic Ischemic Encephalopathy (HIE) is one of the principal causes of neonatal mortality and long-term morbidity worldwide. The neonatal signs of mild cerebral injury are subtle, making an early precise diagnosis difficult. Delayed detection, poor prognosis, and lack of specific biomarkers for the disease are increasing mortality rates. In this study, we intended to identify specific biomarkers using comparative proteomic analysis to predict the severity of perinatal asphyxia so that its outcome can also be prevented.
EXPERIMENTAL DESIGN: A case-control study was conducted on 38 neonates, and urine samples were collected within 24 and 72 h of life. A tandem mass spectrometry-based quantitative proteomics approach, followed by validation via sandwich ELISA, was performed.
RESULTS: The LC-MS/MS-based proteomics analysis resulted in the identification of 1201 proteins in urine, with 229, 244, and 426 being differentially expressed in HIE-1, HIE-2, and HIE-3, respectively. Axon guidance, Diseases of programmed cell death, and Detoxification of reactive oxygen species pathways were significantly enriched in mild HIE versus severe HIE. Among the differentially expressed proteins in various stages of HIE, we chose to validate four proteins - APP, AGT, FABP1, and FN1 - via sandwich ELISA. Individual and cumulative ROC curves were plotted. AGT and FABP1 together showed high sensitivity, specificity, and accuracy as potential biomarkers for early diagnosis of HIE.
CONCLUSION: Establishing putative urinary biomarkers will facilitate clinicians to more accurately screen neonates for brain injury and monitor the disease progression. Prompt treatment of neonates may reduce mortality and neurodevelopmental impairment.
This study will be carried on 30 patients with Chronicobstructivepulmonarydisease. Patients will be selected from department (3) Kaser EL-Ainy, Cairo University.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and concerns treating chronic recurrent allergic diseases of a nasal mucosa and paranasal sinuses by endonasal autolymphocyte therapy. That is ensured by producing lymphocyte self-cells of the patient's venous blood. The produced lymphocytes are cultivated together with prednisolone. The method proceeds with alternate introduction a lymphocyte suspension in dose 0.1 to 3.0 ml in an acceptable medium in concentration 106-107 cl/ml in right and left maxillary sinuses. The introductions are performed every 2 to 6 days. ^ EFFECT: method allows reducing length of treatment, prolonging remission, reducing rate of symptom manifestation of a prior and associated disease. ^ 3 cl, 3 ex, 2 tbl
The invention discloses an application of epicatechin as shown in the formula (I) in preparation of products for preventing or treating leucocytopenia. The leucocytopenia can be caused by antipyretic analgesics, antibiotic, antipsychotics, antithyroid agents, anticarcinogen or radiotherapy. Preferred antipyretic analgesics are selected from amidopyrine, analgin or compound aspirin. Preferred antibiotic is selected from chloramphenicol, penicillin or sulfonamide. Preferred antipsychotics are selected from chlorpromazine, perphenazine and trifluoperazine. Preferred antithyroid agents are selected from propylthiouracil and tapazole. Preferred anticarcinogen is selected from cyclophosphamide. The product is selected from a medicine, a health product or a foodstuff.
BACKGROUND: The cardiomyopathic and neuropathic phenotype of hereditary transthyretin amyloidosis are well recognized. Cardiovascular autonomic dysfunction is less systematically and objectively assessed.
METHODS: Autonomic and clinical features, quantitative cardiovascular autonomic function, and potential autonomic prognostic markers of disease progression were recorded in a cohort of individuals with hereditary transthyretin amyloidosis and in asymptomatic carriers of TTR variants at disease onset (T0) and at the time of the first quantitative autonomic assessment (T1). The severity of peripheral neuropathy and its progression was stratified with the polyneuropathy disability score.
RESULTS: A total of 124 individuals were included (111 with a confirmed diagnosis of hereditary transthyretin amyloidosis, and 13 asymptomatic carriers of TTR variants). Symptoms of autonomic dysfunction were reported by 27% individuals at T0. Disease duration was 4.5 ± 4.0 years [mean ± standard deviation (SD)] at autonomic testing (T1). Symptoms of autonomic dysfunction were reported by 78% individuals at T1. Cardiovascular autonomic failure was detected by functional testing in 75% individuals and in 64% of TTR carriers. Progression rate from polyneuropathy disability stages I/II to III/IV seemed to be shorter for individuals with autonomic symptoms at onset [2.33 ± 0.56 versus 4.00 ± 0.69 years (mean ± SD)].
CONCLUSIONS: Cardiovascular autonomic dysfunction occurs early and frequently in individuals with hereditary transthyretin amyloidosis within 4.5 years from disease onset. Cardiovascular autonomic failure can be subclinical in individuals and asymptomatic carriers, and only detected with autonomic function testing, which should be considered a potential biomarker for early diagnosis and disease progression.
Up to 10 archival breast tumor blocks will be obtained from the Department of Pathology, NUH - half of these blocks will be from patients who were diagnosed before year 2000, and the other half of the blocks will be from patients diagnosed between year 2000-2005 (control specimens). Basic tumor and patient information will be collected without patient identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data. 8-10 ten-micron sections will be cut from each tumor block. RNA will be extracted from the tumor sections using the Roche High Pure FFPE RNA Micro Kit. RNA will be profiled using the Illumina Veracode assay and the Affymetrix Quantigene assay. RNA extraction and gene expression profiling will be performed by collabroators at the Genome Institute of Singapore.
Embodiments may include an automated method for evaluating a sepsis status associated with a blood sample obtained from an individual. Methods may include determining a standard deviation of monocyte volume associated with the blood sample. Methods may include determining a white blood cell count (WBC) associated with the blood sample. Methods may include evaluating, using a data processing module, the sepsis status associated with the blood sample. The data processing module may include a processor and a computer application. This computer application may cause the processor to compare the standard deviation of monocyte volume with a first cutoff value to provide a comparison. The computer application may cause the processor to compare the WBC to a second cutoff to provide a second comparison. The computer application may also cause the processor to evaluate the sepsis status associated with the blood sample based on the first comparison and the second comparison.
Patients' fulfilling Rome III criteria for IBS with symptoms refractory to standard treatment who are referred to a specialist unit for hypnotherapy are consecutively included in the study. Firstly, the patients are invited to a meeting with the nurse for information about the study, check for eligibility and to sign the written informed consent. Exclusion criteria that could influence GI symptoms such as organic GI disease, severe psychiatric comorbidity and pregnancy are controlled for. The patients are randomized to either individual or group treatment given by a nurse trained in hypnotherapy and cognitive behavioral therapy. The randomization is organized and performed in blocks by an external unit connected to the University in order to be accurate. The treatment consists of eight sessions of gut directed hypnotherapy during twelve weeks. A standardized protocol is used and is the same both in the group setting as well as in the individual treatment arm. In each group approximately eight patients are included. Every session lasts for one hour. Outcome measures in the study are GI symptom severity, GI-specific anxiety, psychological distress and health related quality of life. These effects are measured by validated questionnaires at baseline and at various time points during the treatment period as well as after the completion of the treatment and during the 6 months-, 1 and 2 year follow-up.
This study extends on the positive results of a pilot study (Lim et al., 2012) which demonstrated the effectiveness of a cognitive training program combined with perceptual and semantic memory encoding strategies. Following the intervention phase of the pilot study, elements of cognition were examined using standardised assessments. The participants showed improved general attention (p = 0.03), memory (p = 0.03) and cognitive function including naming (p = 0.02), construction (p = 0.01), memory (p = 0.02) and similarities (p = 0.001) all of which are necessary for functioning in daily activities. However, due to the combination of strategies used during the pilot study, the isolated effect of perceptual and semantic memory encoding strategies could not be determined. It has been found that the effects of aging impact negatively on both semantic and perceptual encoding. However, with age, there tends to be a greater impact on an individual's ability to use perceptual encoding strategies in comparison to those of semantic (Kuo, Liu, Ting, \& Chan, 2014). This varies in the case of individuals in the early stages of Alzheimer's disease in which many individuals will show progressive impairment in semantic memory (Hodges \& Patterson, 1995). As dementia has been positively correlated with Mild Cognitive Impairment (MCI) but not often diagnosed until much later in the course of the disease and as not all individuals with MCI will progress to dementia it would be beneficial prior to undertaking a memory encoding intervention program to understand if an individual would benefit greater from undertaking a semantic or a perceptual memory encoding rehabilitation approach. Although it may be easy for a healthy adult to report their preference in encoding style, an individual with MCI or mild dementia may find this more difficult due to the abstract complexity of the concepts. As it is known that not all cases of MCI progress to dementia, this study aims at identifying if individuals with MCI or mild dementia will benefit from intervention based on both semantic and perceptual encoding styles.

In addition, given the benefit and successful use of computer-based programs in elderly, this study will develop the memory encoding training program into a user-friendly computer-based program in healthy older adults, older adults with MCI or mild dementia will be able to use under the guidance of rehabilitation professionals.
Bronchial asthma is a prevalent and increasingly chronic inflammatory lung disease affecting over 300 million people globally. Initially considered an allergic disorder driven by mast cells and eosinophils, asthma is now recognized as a complex syndrome with various clinical phenotypes and immunological endotypes. These encompass type 2 inflammatory endotypes characterized by interleukin (IL)-4, IL-5, and IL-13 dominance, alongside others featuring mixed or non-eosinophilic inflammation. Therapeutic success varies significantly based on asthma phenotypes, with inhaled corticosteroids and beta-2 agonists effective for milder forms, but limited in severe cases. Novel antibody-based therapies have shown promise, primarily for severe allergic and type 2-high asthma. To address this gap, novel treatment strategies are essential for better control of asthma pathology, prevention, and exacerbation reduction. One promising approach involves stimulating endogenous anti-inflammatory responses through regulatory T cells (Tregs). Tregs play a vital role in maintaining immune homeostasis, preventing autoimmunity, and mitigating excessive inflammation after pathogenic encounters. Tregs have demonstrated their ability to control both type 2-high and type 2-low inflammation in murine models and dampen human cell-dependent allergic airway inflammation. Furthermore, microbes, typically associated with disease development, have shown immune-dampening properties that could be harnessed for therapeutic benefits. Both commensal microbiota and pathogenic microbes have demonstrated potential in bacterial-host interactions for therapeutic purposes. This review explores microbe-associated approaches as potential treatments for inflammatory diseases, shedding light on current and future therapeutics.
The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
The placebo group also comprised 17 participants who were given a capsule/tablet of starch rice daily for the same 40-day period. Like the intervention group, participants in the placebo group underwent initial anthropometric and biochemical analyses to set baseline measurements before starting the supplementation period. This group similarly received personalized meal plans to ensure that any observed changes could be accurately attributed to the placebo effect. The placebo group participants were monitored via email and/or text messages to reinforce study guidelines, answer any questions or concerns about their meal plans or supplements, and monitor for any potential adverse effects.
BACKGROUND: Previous work indicates that polygenic risk scores (PRS) for bipolar disorder (BD) are elevated in adults and youth with BD, but whether BD-PRS can inform person-level diagnostic prediction is unknown. Here, we test whether BD-PRS improves performance of a previously published risk calculator (RC) for BD.
METHODS: 156 parents with BD-I/II and their offspring ages 6-18 were recruited and evaluated with standardized diagnostic assessments every two years for >12 years. DNA was extracted from saliva samples, genotyping performed, and BD-PRS calculated based on a 2021 meta-analysis. Using a bootstrapped and cross-validated penalized Cox regression, we assessed whether BD-PRS (alone and interacting with clinical variables) improved RC performance.
RESULTS: Of 227 offspring, 38 developed BD during follow-up. The penalized regression selected BD-PRS and interactions between BD-PRS and parental age at mood disorder onset (AAO), depression, and anxiety. The resulting RC discriminated offspring who developed BD (vs. those that did not) with good accuracy (AUC = 0.81); removing BD-PRS and its interaction terms was associated with a significant decrement to the AUC (decrement = 0.07, p = 0.039). Further exploration of selected interaction terms indicated that all were significant (p-values<0.02), indicating that BD-PRS has a larger effect on the outcome in offspring with depression and anxiety, whose affected parent had a younger AAO.
CONCLUSIONS: The addition of BD-PRS to clinical/demographic predictors in the RC significantly improved its accuracy. BD-PRS predicted BD on the person-level, particularly in offspring of parents with earlier AAO who already had symptoms of anxiety and depression at intake.
BACKGROUND: Autopsy-based radio-pathomic maps of glioma pathology have shown substantial promise inidentifying areas of non-enhancing tumor presence, which may be able to differentiate subsets of patients that respond favorably to treatments such as bevacizumab that have shown mixed efficacy evidence. We tested the hypthesis that phenotypes of non-enhancing tumor fronts can distinguish between glioblastoma patients that will respond favorably to bevacizumab and will visually capture treatment response.
METHODS: T1, T1C, FLAIR, and ADC images were used to generate radio-pathomic maps of tumor characteristics for 79 pre-treatment patients with a primary GBM or high-grade IDH1-mutant astrocytoma for this study. Novel phenotyping (hypercellular, hypocellular, hybrid, or well-circumscribed front) of the non-enhancing tumor front was performed on each case. Kaplan Meier analyses were then used to assess differences in survival and bevacizumab efficacy between phenotypes. Phenotype compartment segmentations generated longitudinally for a subset of 26 patients over the course of bevacizumab treatment, where a mixed effect model was used to detect longitudinal changes.
RESULTS: Well-Circumscribed patients showed significant/trending increases in survival compared to Hypercellular Front (HR = 2.0, p = 0.05), Hypocellular Front (HR = 2.02, p = 0.03), and Hybrid Front tumors (HR = 1.75, p = 0.09). Only patients with hypocellular or hybrid fronts showed significant survival benefits from bevacizumab treatment (HR = 2.35, p = 0.02; and HR = 2.45, p = 0.03, respectively). Hypocellular volumes decreased by an average 50.52 mm3 per day of bevacizumab treatment (p = 0.002).
CONCLUSION: Patients with a hypocellular tumor front identified by radio-pathomic maps showed improved treatment efficacy when treated with bevacizumab, and reducing hypocellular volumes over the course of treatment may indicate treatment response.
The invention relates to a method for manufacturing a liquid acid concentrate for hemodialysis machines, with the following steps. In a preliminary step a water source ( 120 ), an acid source ( 130 ), an electrolyte tank ( 140 ) containing a mixture of electrolytes in exactly the quantity needed for the manufacture of the liquid acid concentrate, and a sodium chloride source ( 150 ) are connected to a mixing tank ( 110 ). During Step a), the quantity of water needed for the manufacture of the batch of liquid acid concentrate is introduced into the mixing tank ( 110 ). At Step b), the quantity of acid needed for manufacture the liquid acid concentrate is introduced into the mixing tank ( 110 ), the solution is stirred until a homogeneous solution is obtained. Step c) is to repeat Sub-steps c1) and c 2 ) until the electrolyte mixture contained in the electrolyte tank is completely dissolved. At Sub-step c 1 ) part of the solution contained in the mixing tank ( 110 ) is transferred into the electrolyte tank ( 140 ) containing the electrolyte mixture, then at Sub-step c 2 ) the solution contained in the electrolyte tank ( 140 ) is transferred into the mixing tank, leaving the still solid constituents in the electrolyte tank. At Step d) the quantity of sodium chloride needed to manufacture the liquid acid concentrate is introduced into the mixing tank ( 110 ). Finally, at Step e), the solution is stirred and recirculated by taking it from the bottom the mixing tank ( 110 ) and reintroducing it at the top of the mixing tank until a homogeneous liquid acid concentrate is obtained. Steps a) to d) can be performed in any order, Step a) preceding always Step c).
Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months on a stable oral ART are treated with DOR/ISL for 144 weeks. Participants will have the option to continue in an optional study extension and receive DOR/ISL for up to an additional 96 weeks or until DOR/ISL is commercially accessible (whichever comes first).